Actively Recruiting
Evaluating Isunakinra With Pembrolizumab-Based Chemotherapy to Enhance Immunotherapy Response in Triple-Negative Breast Cancer
Led by University Health Network, Toronto · Updated on 2026-10-29
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new approach to treat Triple-Negative Breast Cancer TNBC by adding isunakinra, a modified IL-1 receptor antagonist, to standard pembrolizumab-based neoadjuvant chemotherapy NACP. This phase III open-label randomized trial aims to explore whether isunakinra can change the tumor environment by reducing immunosuppressive cells and increasing activated immune cells, potentially improving response to immunotherapy in TNBC patients. The study involves two groups one receiving daily injections of 25 mg isunakinra combined with standard NACP for 24 weeks, and the other receiving only the standard NACP treatment. A total of 60 patients will be randomized evenly between these groups. The trial will monitor the immunologic effects within the tumor and blood to understand the impact of adding isunakinra. Participants will be closely followed during treatment, with evaluations of tumor samples and immune responses to measure changes in the tumor microenvironment. The main outcome is assessing how isunakinra influences tumor-associated macrophages and sensitizes tumors to checkpoint blockade therapy over a 6-year period. Safety, feasibility, and efficacy data will also be collected to guide future studies.
CONDITIONS
Brief Title
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
Research Team
D
Dr. Michael Reedijk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here